MedTrace Logo

Teneligliptin(MP-513) Versus Placebo in Type 2 Diabetes Mellitus

NCT01798238 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 142

Last updated 2014-08-05

No results posted yet for this study

Summary

The study design of this trial is double blind, parallel-group, randomized, placebo controlled study

Conditions

Interventions

DRUG

MP-513

form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day

DRUG

Placebo

Pink film-coated tablet for oral administration, frequency and duration: 1 tablet/day

Sponsors & Collaborators

  • Handok Inc.

    lead INDUSTRY

Principal Investigators

  • Sungwoo Park · Kangbuk Samsung Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01798238 on ClinicalTrials.gov